| 1 | now leaving orexocom to | | | | | | | 3 | 0.59% |
| 2 | 2024 · press release | | | | | | | 3 | 0.59% |
| 3 | go to pr july | | | | | | | 2 | 0.39% |
| 4 | development for opioid overdose | | | | | | | 2 | 0.39% |
| 5 | in development for opioid | | | | | | | 2 | 0.39% |
| 6 | medication in development for | | | | | | | 2 | 0.39% |
| 7 | rescue medication in development | | | | | | | 2 | 0.39% |
| 8 | return return continue disclaimer | | | | | | | 2 | 0.39% |
| 9 | are now leaving orexocom | | | | | | | 2 | 0.39% |
| 10 | leaving orexocom to visit | | | | | | | 2 | 0.39% |
| 11 | information on ox124 a | | | | | | | 2 | 0.39% |
| 12 | new information on ox124 | | | | | | | 2 | 0.39% |
| 13 | shares new information on | | | | | | | 2 | 0.39% |
| 14 | orexo shares new information | | | | | | | 2 | 0.39% |
| 15 | disclaimer you are now | | | | | | | 2 | 0.39% |
| 16 | return continue disclaimer you | | | | | | | 2 | 0.39% |
| 17 | you are now leaving | | | | | | | 2 | 0.39% |
| 18 | the privacy policy of | | | | | | | 2 | 0.39% |
| 19 | continue disclaimer you are | | | | | | | 2 | 0.39% |
| 20 | work ranked among top | | | | | | | 2 | 0.39% |
| 21 | sustainability work ranked among | | | | | | | 2 | 0.39% |
| 22 | 2024 interim report 8 | | | | | | | 2 | 0.39% |
| 23 | ab´s sustainability work ranked | | | | | | | 2 | 0.39% |
| 24 | orexo ab´s sustainability work | | | | | | | 2 | 0.39% |
| 25 | us residents and healthcare | | | | | | | 2 | 0.39% |
| 26 | for us residents and | | | | | | | 2 | 0.39% |
| 27 | orexo q2 2024 interim | | | | | | | 2 | 0.39% |
| 28 | q2 2024 interim report | | | | | | | 2 | 0.39% |
| 29 | intended for us residents | | | | | | | 2 | 0.39% |
| 30 | press release · regulatory | | | | | | | 2 | 0.39% |
| 31 | 26 april 2024 26 | | | | | | | 1 | 0.20% |
| 32 | ab’s annual general meeting | | | | | | | 1 | 0.20% |
| 33 | orexo ab’s annual general | | | | | | | 1 | 0.20% |
| 34 | from orexo ab’s annual | | | | | | | 1 | 0.20% |
| 35 | report from orexo ab’s | | | | | | | 1 | 0.20% |
| 36 | · regulatory report from | | | | | | | 1 | 0.20% |
| 37 | regulatory report from orexo | | | | | | | 1 | 0.20% |
| 38 | jump to content orexo | | | | | | | 1 | 0.20% |
| 39 | april 2024 26 april | | | | | | | 1 | 0.20% |
| 40 | interim report 8 july | | | | | | | 1 | 0.20% |